Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis. (2025). SKIN The Journal of Cutaneous Medicine, 9(2). https://doi.org/10.25251/skin.10.supp.527